|
1.
|
AI McClatcheyNeurofibromatosisAnnu Rev
Pathol2191216200710.1146/annurev.pathol.2.010506.091940
|
|
2.
|
K JettJM FriedmanClinical and genetic
aspects of neurofibromatosis 1Genet
Med12111201010.1097/GIM.0b013e3181bf15e3
|
|
3.
|
A SavarDM CestariNeurofibromatosis type I:
genetics and clinical manifestationsSemin
Ophthalmol234551200810.1080/0882053070174522318214791
|
|
4.
|
B DasguptaDH GutmannNeurofibromatosis 1:
closing the GAP between mice and menCurr Opin Genet
Dev132027200310.1016/S0959-437X(02)00015-112573431
|
|
5.
|
SR GrobmyerJD ReithA ShahlaeeCH BushSN
HochwaldMalignant peripheral nerve sheath tumor: molecular
pathogenesis and current management considerationsJ Surg
Oncol97340349200810.1002/jso.20971
|
|
6.
|
D KatzA LazarD LevMalignant peripheral
nerve sheath tumour (MPNST): the clinical implications of cellular
signalling pathwaysExpert Rev Mol
Med11e30200910.1017/S146239940900122719835664
|
|
7.
|
DG EvansME BaserJ McGaughranS SharifE
HowardA MoranMalignant peripheral nerve sheath tumours in
neurofibromatosis 1J Med
Genet39311314200210.1136/jmg.39.5.31112011145
|
|
8.
|
D MuirD NeubauerIT LimAT YachnisMR
WallaceTumorigenic properties of neurofibromin-deficient
neurofibroma Schwann cellsAm J
Pathol158501513200110.1016/S0002-9440(10)63992-211159187
|
|
9.
|
A GuptaBH CohenP RuggieriRJ PackerPC
PhillipsPhase I study of thalidomide for the treatment of plexiform
neurofibroma in neurofibromatosis
1Neurology60130132200310.1212/01.WNL.0000042321.94839.7812525736
|
|
10.
|
EC CitakA OguzC KaradenizA OkurL MemisO
BoyunagaManagement of plexiform neurofibroma with inter-feron
alphaPediatr Hematol Oncol25673678200810.1080/08880010802315983
|
|
11.
|
D Babovic-VuksanovicK BallmanV
MichelsPhase II trial of pirfenidone in adults with
neurofibromatosis type
1Neurology6718601862200610.1212/01.wnl.0000243231.12248.6717035676
|
|
12.
|
BC WidemannWL SalzerRJ ArceciPhase I trial
and pharmacokinetic study of the farnesyltransferase inhibitor
tipifarnib in children with refractory solid tumors or
neurofibromatosis type I and plexiform neurofibromasJ Clin
Oncol24507516200610.1200/JCO.2005.03.8638
|
|
13.
|
Y KinebuchiW NoguchiY IgawaO
NishizawaRecurrent retroperitoneal malignant nerve sheath tumor
associated with neurofibromatosis type 1 responding to carboplatin
and etoposide combined chemotherapyInt J Clin
Oncol10353356200510.1007/s10147-005-0495-8
|
|
14.
|
H LandyL FeunA MarkoeExtended remission of
a recurrent median nerve malignant peripheral nerve sheath tumor
after multimodal treatment. Case reportJ
Neurosurg103760763200510.3171/jns.2005.103.4.0760
|
|
15.
|
VM MorettiEA CrawfordAP StaddonRD
LackmanCM OgilvieEarly outcomes for malignant peripheral nerve
sheath tumor treated with chemotherapyAm J Clin
Oncol34417421201110.1097/COC.0b013e3181e9c08a20838322
|
|
16.
|
JR KroepM OualiH GelderblomFirst-line
chemotherapy for malignant peripheral nerve sheath tumor (MPNST)
versus other histological soft tissue sarcoma subtypes and as a
prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma
group studyAnn Oncol22207214201110.1093/annonc/mdq338
|
|
17.
|
A FerrariR MiceliA ReyNon-metastatic
unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas:
results of a pooled analysis from United States and European
groupsEur J
Cancer47724731201110.1016/j.ejca.2010.11.01321145727
|
|
18.
|
JA McCubreyLS SteelmanSL AbramsRoles of
the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant
transformation and drug resistanceAdv Enzyme
Regul46249279200610.1016/j.advenzreg.2006.01.00416854453
|
|
19.
|
P BholaS BanerjeeJ MukherjeePreclinical in
vivo evaluation of rapamycin in human malignant peripheral nerve
sheath explant xenograftInt J
Cancer126563571201010.1002/ijc.2478319634141
|
|
20.
|
G AmbrosiniHS CheemaS SeelmanSorafenib
inhibits growth and mitogen-activated protein kinase signaling in
malignant peripheral nerve sheath cellsMol Cancer
Ther7890896200810.1158/1535-7163.MCT-07-051818413802
|
|
21.
|
N HoltkampE MalzerJ ZietschEGFR and erbB2
in malignant peripheral nerve sheath tumors and implications for
targeted therapyNeuro
Oncol10946957200810.1215/15228517-2008-05318650488
|
|
22.
|
JW WojtkowiakF FouadDT LaLondeInduction of
apoptosis in neurofibromatosis type 1 malignant peripheral nerve
sheath tumor cell lines by a combination of novel farnesyl
transferase inhibitors and lovastatinJ Pharmacol Exp
Ther326111200810.1124/jpet.107.135830
|
|
23.
|
SY JeongSJ ParkHJ KimThe spectrum of NF1
mutations in Korean patients with neurofibromatosis type 1J Korean
Med Sci21107112200610.3346/jkms.2006.21.1.10716479075
|
|
24.
|
SY JeongJH HanYY ParkHJ KimIdentification
of differentially expressed genes related to NF1-associated
malignant transformation from a patient with neurofibromatosis type
1Genes Genomics304074182008
|
|
25.
|
Y LiPK RaoR WenNotch and Schwann cell
transformationOncogene2311461152200410.1038/sj.onc.120706814762442
|
|
26.
|
TN BasuDH GutmannJA FletcherTW GloverFS
CollinsJ DownwardAberrant regulation of ras proteins in malignant
tumour cells from type 1 neurofibromatosis
patientsNature356713715199210.1038/356713a01570015
|
|
27.
|
T OltersdorfSW ElmoreAR ShoemakerAn
inhibitor of Bcl-2 family proteins induces regression of solid
tumoursNature435677681200510.1038/nature0357915902208
|
|
28.
|
E LegiusDA MarchukFS CollinsTW
GloverSomatic deletion of the neurofibromatosis type 1 gene in a
neurofibrosarcoma supports a tumour suppressor gene hypothesisNat
Genet3122126199310.1038/ng0293-1228499945
|
|
29.
|
T KogaH IwasakiM IshiguroA MatsuzakiM
KikuchiFrequent genomic imbalances in chromosomes 17, 19, and 22q
in peripheral nerve sheath tumours detected by comparative genomic
hybridization analysisJ
Pathol19798107200210.1002/path.110112081210
|
|
30.
|
S SubramanianV ThayanithyRB
WestGenome-wide transcriptome analyses reveal p53 inactivation
mediated loss of miR-34a expression in malignant peripheral nerve
sheath tumoursJ Pathol2205870201010.1002/path.2633
|
|
31.
|
A HarderM RoscheDE ReussMethylation
analysis of the neurofibromatosis type 1 (NF1) promoter in
peripheral nerve sheath tumoursEur J
Cancer4028202828200410.1016/j.ejca.2004.07.02115571966
|
|
32.
|
L SevillaA ZaldumbideP PognonecKE
BoulukosTranscriptional regulation of the bcl-x gene encoding the
anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1
transcription factor familiesHistol
Histopathol16595601200111332715
|
|
33.
|
V KirkinS JoosM ZornigThe role of Bcl-2
family members in tumorigenesisBiochim Biophys
Acta1644229249200410.1016/j.bbamcr.2003.08.00914996506
|
|
34.
|
SA AmundsonTG MyersD ScudieroS KitadaJC
ReedAJ Fornace JrAn informatics approach identifying markers of
chemosensitivity in human cancer cell linesCancer
Res6061016110200011085534
|
|
35.
|
JE LittlejohnX CaoSD MillerBcl-xL
antisense oligonucleotide and cisplatin combination therapy extends
survival in SCID mice with established mesothelioma xenograftsInt J
Cancer123202208200810.1002/ijc.23452
|
|
36.
|
E BrotinM Meryet-FiguiereK SimoninBcl-XL
and MCL-1 constitute pertinent targets in ovarian carcinoma and
their concomitant inhibition is sufficient to induce apoptosisInt J
Cancer1268858952010
|
|
37.
|
AS AzmiRM MohammadNon-peptidic small
molecule inhibitors against Bcl-2 for cancer therapyJ Cell
Physiol2181321200910.1002/jcp.2156718767026
|
|
38.
|
A RichardsonSB KayePharmacological
inhibition of the Bcl-2 family of apoptosis regulators as cancer
therapyCurr Mol
Pharmacol1244254200810.2174/187446721080103024420021437
|
|
39.
|
D ReynosoLK NoldenD YangSynergistic
induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib
mesylate in gastrointestinal stromal tumor cellsMol
Oncol593104201110.1016/j.molonc.2010.10.00321115411
|
|
40.
|
MF van DelftAH WeiKD MasonThe BH3 mimetic
ABT-737 targets selective Bcl-2 proteins and efficiently induces
apoptosis via Bak/Bax if Mcl-1 is neutralizedCancer
Cell10389399200617097561
|
|
41.
|
C TouzeauC DoussetL BodetABT-737 induces
apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low
profile and synergizes with other antineoplastic agentsClin Cancer
Res1759735981201110.1158/1078-0432.CCR-11-095521821698
|
|
42.
|
M UgarenkoA NudelmanA RephaeliK KimuraDR
PhillipsSM CuttsABT-737 overcomes Bcl-2 mediated resistance to
doxorubicin-DNA adductsBiochem
Pharmacol79339349201010.1016/j.bcp.2009.09.00419737541
|
|
43.
|
D LimJ MuirImatinib for chronic myeloid
leukaemia: a NICE
messLancet3581903200110.1016/S0140-6736(01)06903-311741656
|
